![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles |
Hung-Yao Lin, Tai-Chung Tseng |
Clin Mol Hepatol. 2022;28(2):181-182. Published online 2022 February 21 DOI: https://doi.org/10.3350/cmh.2022.0028 |
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis PGI3 Comparative Safety of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in Chronic Hepatitis B Patients Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide O-043: Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use Should we switch to Tenofovir Alafenamide for all Patients with Chronic Hepatitis B? Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B Tenofovir Alafenamide: A Review in Chronic Hepatitis B Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply |
This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015. |